An Automated Organoid Platform with Inter-organoid Homogeneity and Inter-patient Heterogeneity
Open accessAbstract
Current organoid technologies require intensive manual manipulation and lack uniformity in organoid size and cell composition. We present here an automated organoid platform that generates uniform organoid precursors in high-throughput. This is achieved by templating from monodisperse Matrigel droplets and sequentially delivering them into wells using a synchronized microfluidic droplet printer. Each droplet encapsulates a certain number of cells (e.g., 1,500 cells), which statistically represent the heterogeneous cell population in a tumor section. The system produces >400-μm organoids within 1 week with both inter-organoid homogeneity and inter-patient heterogeneity. This enables automated organoid printing to obtain one organoid per well. The organoids recapitulate 97% gene mutations in the parental tumor and reflect the patient-to-patient variation in drug response and sensitivity, from which we obtained more than 80% accuracy among the 21 patients investigated. This organoid platform is anticipated to fulfill the personalized medicine goal of 1-week high-throughput screening for cancer patients.
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Droplet microfluidics was used to aggregate murine cholangiocytes into complex organoids with liver mesenchymal cells.
“droplet microfluidics was used to aggregate murine cholangiocytes to form complex organoids with liver mesenchymal cells74.”
From Organoids (2022) · cites this paper as [74]
The Results (The Automated Organoid Platform; Inter-organoid Homogeneity, pages not provided) describe droplet-based microfluidic production of organoids, including mouse liver organoids. Our copy does not identify the cells used for those liver organoids as murine cholangiocytes or say they were aggregated with liver mesenchymal cells. (LLM, conf=0.86)
Experimental — accuracy not yet measuredDuctal cell-liver mesenchymal cell co-cultures have been shown to recapitulate part of the liver portal tract architecture.
“Recently, ductal cell-liver mesenchymal cell co-cultures have been shown to recapitulate part of the liver portal tract architecture74.”
From Organoids (2022) · cites this paper as [74]
The Results sections on Inter-organoid Homogeneity and Organoid Validation by Histology and Gene Expression describe liver organoid epithelium and mixed epithelial–fibroblast cultures (page unavailable). They do not identify ductal cell–liver mesenchymal cell co-cultures or report reconstruction of portal tract architecture. Searches for those cell types and for “portal tract” found no passage addressing the claim. (LLM, conf=0.76)
Experimental — accuracy not yet measuredsiVEGFR-loaded nanoparticles effectively inhibited angiogenic sprouting without affecting the viability of endothelial cells.
“It was demonstrated that the siVEGFR‐loaded nanoparticles effectively inhibited the angiogenic sprouting without affecting the viability of endothelial cells.”
From 3D Biomimetic Models to Reconstitute Tumor Microenvironment In Vitro: Spheroids, Organoids, and Tumor‐on‐a‐Chip (2023) · cites this paper as [116]
The Results section describes anticancer-drug responses in tumor organoids, and STAR★Methods describes viability assays on those organoids (page numbers unavailable). Searches for siVEGFR-loaded nanoparticles, angiogenic sprouting, and endothelial-cell viability found no passage addressing the claim in our copy. (LLM, conf=0.76)
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
The citation lists haven’t been fetched yet
References 39 · Cited by 188
- Authors
- Jiang, S., Zhao, H., Zhang, W., Wang, J., Liu, Y., Cao, Y., Zheng, H., Hu, Z., Wang, S., Zhu, Y., Wang, W., Cui, S., Lobie, P. E., Huang, L., & Ma, S.
- Affiliations
- Tsinghua–Berkeley Shenzhen Institute (CN)
- First Affiliated Hospital of Zhengzhou University (CN)
- Tsinghua University (CN)
- Peking University Shenzhen Hospital (CN)
- Shenzhen University (CN)
- Guangzhou Medical University Cancer Hospital (CN)
- Corresponding author
- Huang, Laiqiang
- Ma, Shaohua
- ORCID
- Venue
- Cell Reports Medicine
- Publisher
- Elsevier BV
- Published
- 2020-12
- Volume
- 1
- Issue
- 9
- Pages
- 100161
- ISSN
- 2666-3791 (ISSN-L)
- PMC
- PMC7762778
- OpenAlex
- W3115787212
- Cited by
- 188
- References
- 39
- Citations by year
- 2026: 42 · 2025: 51 · 2024: 33 · 2023: 24 · 2022: 31 · 2021: 7
- FWCI
- 4.87
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Cell Reports Medicine (publishedVersion, cc-by-nc-nd)
- PubMed Central (publishedVersion, cc-by-nc-nd)
- PubMed (publishedVersion)
- Rare & Special e-Zone (The Hong Kong University of Science and Technology) (submittedVersion)
- Funders
- Shenzhen Science and Technology Innovation Program
- Development and Reform Commission of Shenzhen Municipality
- National Natural Science Foundation of China
- Topics
- Physical Sciences › Engineering › Biomedical Engineering › 3D Printing in Biomedical Research
- Health Sciences › Medicine › Oncology › Cancer Cells and Metastasis
- Physical Sciences › Engineering › Biomedical Engineering › Innovative Microfluidic and Catalytic Techniques Innovation
- Keywords
- organoids, interpatient heterogeneity, tumor heterogeneity, drug response prediction, personalized medicine, anticancer drug screening
- MeSH terms
- Animals, Automation, Biometry, Humans, Neoplasms, Organoids, Microfluidics, Mice, High-Throughput Screening Assays, Precision Medicine, Printing, Three-Dimensional
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
